On Tuesday, Shares of Clean Diesel Technologies Inc. (NASDAQ:CDTI), surged 22.93% to $2.52, after the global vehicle emissions control system provider released initial vehicle test results for Spinel, its proprietary clean emissions exhaust technology.
“These encouraging initial results from rigorous FTP testing demonstrate the noteworthy potential of our Spinel technology,” CEO Chris Harris said.
Clean Diesel Technologies, Inc. manufactures and distributes light duty vehicle catalysts and heavy duty diesel emissions control systems and products to automakers, distributors, integrators, and retrofitters in the United States, Canada, Sweden, and the United Kingdom.
Shares of Halliburton Company (NYSE:HAL), inclined 1.50% to $45.92, during its last trading session, after the oil services company had coverage initiated with an “overweight” rating by analysts at JPMorgan recently.
While analysts Sean Meakim and Alexander Merchant initiated coverage on the entire oil services sector with a cautious outlook, the firm believes that large scale service providers like Halliburton still have potential upside.
Halliburton received a $51 price target, which represents a potential 12% upside from the stock’s current price.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
At the end of Tuesday’s trade, Shares of Juno Therapeutics Inc. (NASDAQ:JUNO), gained 6.60% to $56.57.
Juno Therapeutics, declared that it has attained X-BODY, Inc., a privately held biotechnology company with nine employees based in Waltham, Massachusetts. The acquisition furthers Juno’s strategy of investing in technologies that augment the company’s capabilities to create best-in-class engineered T cells against a broad array of cancer targets. The acquisition brings in-house to Juno an innovative discovery platform that interrogates the human antibody repertoire, rapidly selecting fully human antibodies with desired characteristics, even against difficult targets.
Juno will incorporate this platform into its process for creating CAR T constructs, using it to generate new binding domains from fully-human naive single chain variable fragment (scFv)-formatted libraries. Fully-human scFv’s have the potential for reduced immunogenicity and improved CAR T cell in vivo persistence. Juno also plans to continue to explore the broader application of the technology to alternative antigen-binding platforms, counting its TCR platform.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Finally, Alcatel-Lucent (NYSE:ALU), ended its last trade at $3.93.
Alcatel-Lucent executives defended their plan to sell their company to Finland’s Nokia Corp., telling skeptical shareholders that it is the only option for a firm that lacks “critical mass” against giants like Ericsson and Huawei Technologies, WallStreet Journal Stated.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
